肺線維症の救出策:自然製品の複数の経路による治療
Yujia Weng1, Baoli He1, Jialin Zhou2
1Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
まとめ
肺線維症 (PF) の治療には自然製品が有望で 複数の病気の経路を標的としています これらの天然化合物のさらなる研究は PFに対する新しい治療法につながる可能性があります.
科学分野:
- 薬理学について
- 自然製品化学
- 肺医学
背景:
- 肺線維症 (PF) の病原性は完全に理解されていません.
- PFのような複雑な病気を 治療する可能性を秘めています
- 生物学的利用可能性の課題は,天然製品の製剤の最適化を必要とする.
研究 の 目的:
- PFの処理における天然製品のメカニズムの見直し
- PF治療の潜在的治療標的を特定する.
主な方法:
- PubMed,Web of Science,および薬理学のテキストの包括的な文献検索.
- キーワードには肺線維症,天然製品 (アルカロイド,テルペノイド,フラボノイド,サポニン),炎症,酸化ストレスが含まれています.
- PF処理における天然製品の潜在的なメカニズムに焦点を当てます.
主要な成果:
- 自然な製品は,抗炎症,抗酸化ストレス,上皮-メゼンキマ移行 (EMT) と内皮-メゼンキマ移行 (EndMT) を阻害し,線維細胞活性化を標的とし,代謝ホメオスタシスを調節し,オートファギーを促進し,老化/アポトーシスを抑制します.
- 主な調節経路には,TGF-β1/SMAD,PI3K/Akt/mTOR,NOX4-Nrf2,AMPK,NF-κB,STAT3が含まれている.
- 毒性,副作用,臨床問題,および制限についても議論されます.
結論:
- 解明されたメカニズムは 既存の天然製品の新しい応用をサポートします
- このレビューは,PFの予防と治療のための天然製品に関する将来の研究のための洞察を提供します.
関連する概念動画
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
252
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
252
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
256
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
256
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
224
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
224
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
318
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
318
01:30Pulmonary Hypertension: Classification and Pathogenesis
285
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
285
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
248
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
248